Clinical Trial Update: Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting long-term safety and efficacy of nemolizumab in adults with moderate-to-severe atopic dermatitis; status indicates active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Moderate-to-Severe Atopic Dermatitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING